

## GENE EXPRESSION

## How do lncRNAs regulate transcription?

Yicheng Long,<sup>1\*</sup> Xueyin Wang,<sup>1\*</sup> Daniel T. Youmans,<sup>1,2\*</sup> Thomas R. Cech<sup>1†</sup>

It has recently become apparent that RNA, itself the product of transcription, is a major regulator of the transcriptional process. In particular, long noncoding RNAs (lncRNAs), which are so numerous in eukaryotes, function in many cases as transcriptional regulators. These RNAs function through binding to histone-modifying complexes, to DNA binding proteins (including transcription factors), and even to RNA polymerase II. In other cases, it is the act of lncRNA transcription rather than the lncRNA product that appears to be regulatory. We review recent progress in elucidating the molecular mechanisms by which lncRNAs modulate gene expression and future opportunities in this research field.

## INTRODUCTION

Deep sequencing of mammalian transcriptomes has revealed the remarkable fact that there are plausibly more than 100,000 different RNAs produced in the organism, far exceeding the ~20,000 protein-coding genes. Most of these RNA sequences are noncoding. It has been useful in the field to define the long noncoding RNAs (lncRNAs) as those >200 nucleotides (nt), thereby separating them from the distinct classes of microRNAs (miRNAs), small nuclear RNAs (snRNAs), and small nucleolar RNAs (snoRNAs) that function through distinct mechanisms. However, this is admittedly an arbitrary cutoff, and in this Review, we will include B2 RNA (~180 nt) as an “honorary lncRNA” because it reveals an important mechanism about how noncoding RNAs can inhibit transcription.

We are deliberately vague about the number of lncRNAs, because deep-sequencing experiments always require a cutoff of some minimum number of reads. It is more difficult to conceive a function for a lncRNA that is present at less than one copy per cell than for lncRNAs that are more abundant. Very rare or unstable lncRNAs could be transcriptional noise. Furthermore, many researchers study one cell type, but lncRNAs are often specific to particular cell types (1). Thus, their total numbers may be underestimated. Enhancer RNAs (eRNAs) alone constitute an enormous class [reviewed by Li *et al.* (2)]; if eRNAs were transcribed from every active enhancer, then this class alone would number in the hundreds of thousands when all cell types are considered.

The lncRNAs can be nuclear, nucleolar, or cytoplasmic or occupy several cellular compartments. The cellular localization of a lncRNA is informative regarding its function. For example, nuclear lncRNAs could plausibly have functions in histone modification or direct transcriptional regulation. If a lncRNA has a substantial cytoplasmic component, then the possibility that it contains a short open reading frame that is translated should be considered.

Some lncRNAs may function at the RNA level, for example, as ribozymes or riboswitches (3). Most commonly, however, lncRNAs perform their functions as ribonucleoprotein particles (RNPs). In terms of the protein partners of the lncRNAs, it is useful to know whether they bind RNAs highly specifically or more promiscuously. For example, U1A protein appears to have predominantly two RNA partners (U1 snRNA and its own mRNA), and TERT protein has one established RNA partner [telomerase RNA (TR)]. Admittedly, the number of known RNA partners tends to increase as more research is done. For example,

yeast Pop1/Pop6/Pop7 was initially found as a component of two RNPs, ribonuclease (RNase) P and RNase MRP, and then more recently as a functional component of yeast telomerase (4), and additional functional partners could exist. At the other extreme, heterogeneous nuclear RNP (hnRNP) proteins, PRC2 (Polycomb repressive complex 2) and FUS proteins have very large transcriptomes, binding many thousands of RNAs in cells (5); correspondingly, they bind many RNAs in vitro with similar binding constants (6, 7).

Many proteins known to be involved in eukaryotic transcription, most of which are therefore DNA binding proteins, also bind lncRNAs in vitro and in vivo. The proteins may have separate sites for binding RNA and DNA, or the two nucleic acids may bind mutually exclusively in overlapping binding modes [reviewed by Hudson and Ortlund (8)]. In some of the latter cases, it is possible that the dual binding is fortuitous: The protein has a DNA binding site, which therefore has more or less ability to bind RNA, and the RNA binding may have little consequence. In many cases, however, there is evidence that the RNA binding is regulatory. In a very general sense, we can think of several ways in which lncRNAs could regulate transcription, as follows:

**(1) Recruitment**

RNA can recruit a regulatory protein complex to a gene or an entire chromosome in cis (when the nascent RNA still occupies its site of transcription) or in trans (for example, by base pairing with another RNA, by RNA binding directly to DNA, or by RNA-protein interactions).

**(2) Inhibition**

RNA can inhibit the binding of a transcriptional regulatory factor by acting as a “decoy” or inhibit its activity by direct active-site occlusion, by allosteric effects, or more indirectly.

**(3) Indirectly, through the act of transcription**

Transcription of a lncRNA may regulate the transcription of nearby mRNA genes, either positively (maintaining active chromatin structure) or negatively (for example, colliding polymerases). In these cases, the RNA product may have no importance at all, or it could have an additional function.

**(4) Indirectly, through genome organization and the architecture of the nucleus**

Organizing hetero- or euchromatic regions into close proximity may stabilize these domains and/or control the spreading of posttranslational modifications (PTMs) to nearby chromatin.

As we traverse the landscape of recent research in this area, we will encounter examples where each of these features appears to be used. Because this is a very new field, the mechanistic understanding is still

Copyright © 2017  
The Authors, some  
rights reserved;  
exclusive licensee  
American Association  
for the Advancement  
of Science. No claim to  
original U.S. Government  
Works. Distributed  
under a Creative  
Commons Attribution  
NonCommercial  
License 4.0 (CC BY-NC).

<sup>1</sup>Department of Chemistry and Biochemistry, University of Colorado BioFrontiers Institute, and Howard Hughes Medical Institute, University of Colorado, Boulder, CO 80309, USA. <sup>2</sup>Anschutz Medical Campus, University of Colorado Denver, Aurora, CO 80045, USA.

\*These authors contributed equally to this work.

†Corresponding author. Email: thomas.cech@colorado.edu

a work in progress. Therefore, at the end of the review, we will present our ideas about the type of experiments that should be considered if one wants to really nail down the mechanisms of RNA-mediated transcriptional regulation.

### B2 RNA REGULATES RNA POLYMERASE II BY DIRECT BINDING

Transcription is broadly dysregulated in response to heat shock (9). Chaperones and heat shock proteins, such as HSP70, are transcriptionally up-regulated, whereas housekeeping genes, such as actin and hexokinase II, are down-regulated (10–12). The mouse B2 noncoding RNA is both up-regulated in response to heat shock and coordinates proper gene expression during organogenesis (13–16). The ~180-nt B2 RNA is synthesized by polymerase III (Pol III) and belongs to the short interspersed nuclear elements (SINEs) family, transcribed from retrotransposons that are interspersed throughout the mouse genome (17–20). It was not until this past decade that B2 RNA became appreciated as one of the master regulators of gene expression during heat shock.


To understand the function of B2 up-regulation, Allen and colleagues (18) inhibited total Pol III transcription and performed antisense oligonucleotide knockdowns of B2 RNA during heat shock. Decreased accumulation of B2 RNA corresponded to an up-regulation of coding genes that were previously down-regulated (18). This result was further corroborated by the finding that RNA Pol II transcription in nuclear lysates was significantly inhibited in the presence of B2 RNA, but not by the control B1 RNA (18, 20). These data prompted the inquiry of how the mature B2 noncoding transcript inhibits RNA Pol II transcription.

RNA immunoprecipitation (RIP) studies demonstrated that B2 RNA is enriched in RNA Pol II purifications (18). Although RIP is useful for identifying candidate RNA-protein interactions, it is unable to define direct binding partners and can suffer from RNA-protein exchange in extracts (21). However, in the current case, follow-up electrophoretic mobility shift studies and functional *in vitro* transcriptional assays showed that B2 RNA inhibits transcription by associating directly with the preinitiation complex (Fig. 1) (20). This mechanism of inhibition paralleled findings in *Escherichia coli*, where the 184-nt 6S RNA was found to inhibit transcription by binding to the RNA polymerase- $\sigma^{70}$  holoenzyme (22).

Deletion analysis on B2 RNA coupled with RNA Pol II RNase protection assays determined that the 3' region of the transcript is responsible for binding to RNA Pol II (20). Additionally, experimental determination of the B2 RNA secondary structure showed that the 3' end of the noncoding transcript has several stem-loop and single-stranded regions (20). Deletion of a single-stranded region affects the ability of B2 RNA to repress transcription, whereas it has no effect on binding to RNA Pol II (23). This contrasts with how disruption of the RNA stem loop prevents binding to RNA Pol II and transcriptional repression (20).

Further work identified additional small RNAs, such as Alu and Fc, that compete with B2 RNA for Pol II binding and inhibition (24, 25). A recent cocrystal structure of RNA Pol II and the Fc RNA revealed that the Fc RNA inhibitor binding site is unique but has significant overlap with the canonical nucleic acid docking site in the elongation complex (25). This cocrystal structure is entirely consistent with the previously reported mechanism of RNA-mediated inhibition.

Multiple independent research groups conducting both *in vitro* and *in vivo* assays have accumulated a conclusive body of evidence defining



**Fig. 1. B2 RNA directly inhibits transcription.** In the absence of B2 RNA, a functional closed preinitiation complex (PIC) can assemble. **(Top)** This complex can melt the dsDNA duplex, forming an open preinitiation complex to promote transcription initiation. In contrast, B2 RNA directly binds to RNA Pol II in a nonfunctional closed complex. **(Bottom)** B2 RNA precludes Pol II from making functional DNA contacts and thereby prevents dsDNA melting and open complex formation.

the mechanism of B2 RNA-mediated transcriptional repression. It is now clear that B2 RNA inhibits transcription through a direct interaction with RNA Pol II and prevents the formation of a functional closed preinitiation complex. However, the downstream function of B2-mediated repression and determining why certain RNA Pol II transcripts are up-regulated in response to heat shock are still areas of active research. For example, a recent model suggested that whereas there is global up-regulation of B2 RNA in heat shock, there is local degradation of B2 RNA at sites of active transcription (26). This local degradation of B2 RNA at stress response genes then induces an up-regulation of these RNA Pol II transcripts relative to the level of global RNA Pol II transcription (26).

### roX RNAs ARE ESSENTIAL FOR THE HYPERACTIVE X CHROMOSOME IN DROSOPHILA MALES

*Drosophila melanogaster* and *Homo sapiens* both require X chromosome dosage compensation, because the female genome comprises two X chromosomes and the male genome carries one. *H. sapiens* resolve the problem by compacting one X chromosome in females through epigenetic modifications (27). The result is a silent X chromosome, referred to as the Barr body. In contrast, *D. melanogaster* acetylate histones on the male X chromosome, resulting in hyperactive transcription (28, 29). Although these processes seem entirely divergent, they are linked by the common feature of lncRNAs directing epigenetic modifications (30).

*D. melanogaster* express two lncRNAs on the male X chromosome, referred to as RNA on the X 1 and 2 (roX1 and roX2) (31, 32). roX1 (3.7 kb) and roX2 (1.1 kb) display overlapping functions; either one can be deleted, but deletion of both results in male lethality (31, 33). Additionally, transgenic expression of either roX RNA can rescue the lethal phenotype of roX RNA deletion (32, 34).

Elegant immunofluorescence and RNA fluorescence *in situ* hybridization studies identified that roX RNAs normally coat one X chromosome, and they spread *in cis* across autosomal chromosomes when they are ectopically expressed (31–35). Additional imaging studies showed that roX RNAs colocalize perfectly with a male-specific protein complex that includes five proteins: maleless (MLE), male-specific

lethal 1 to 3 (MSL1 to MSL3), and males absent on the first (MOF) (31–35). It was quickly suggested, and later confirmed, that together these proteins and RNAs form the dosage compensation complex (DCC), which generates the hyperactive X chromosome (36).

In males, the DCC ribonucleoprotein complex coats one X chromosome and acetylates Lys<sup>16</sup> on histone 4 (H4K16Ac) (Fig. 2) (36–39). H4K16Ac is deposited across much of the X chromosome, and there is a consensus that this PTM is essential for creating hyperactive transcription (36–40).

The roX RNAs naturally adopt a repetitive tandem stem-loop conformation (41, 42). This was predicted by a chemical probing method [SHAPE (selective 2'-hydroxyl acylation analyzed by primer extension)], as well as experimentally corroborated (41, 42). Cross-linking studies coupled to RNA mutagenesis identified MLE and MSL2 as the major RNA binding partners of the roX RNAs (41). Additionally, the MLE helicase remodels the tandem stem-loop structure of roX RNAs into a different stem-loop structure that attains a higher binding affinity toward MLE and MSL2 (42–44). This remodeled structure was also experimentally observed as the active chromatin-bound RNA *in vivo* and is dependent on the adenosine triphosphatase (ATPase) activity of MLE (42–44).


Although MLE and MSL2 appear to be the major RNA binding proteins within the DCC (41), the chromodomains of MOF and MSL3 have also been suggested to play a role in roX RNA recognition

(37). Furthermore, protein mutagenesis and immunoprecipitation studies suggest that the affinity of MSL3 toward roX RNAs is affected by acetylation at a single lysine residue (45).


It is quite clear that the DCC is a ribonucleoprotein complex and that roX RNAs are essential for targeting the DCC to the X chromosome. However, we still do not fully understand how roX RNAs contribute to DCC recruitment. The DCC is known to have high affinity toward certain genomic sites (46–48). One model is that incorporation of roX RNAs into the DCC increases the affinity toward these high-affinity DNA binding sites and decreases the affinity toward nonspecific regions (49). Another model is that additional protein partners could be driving the specificity of the DCC toward DNA recognition elements (30, 50). Thus, after 20 years of active research, the precise role of roX RNAs in X-chromosome hyperactivation remains an active question in the field.

### PRC2, Spen/SHARP, AND Xist: INACTIVATION OF A WHOLE CHROMOSOME

PRC2 is an essential histone methyltransferase required for gene silencing during development and cancer. PRC2 binds both lncRNAs and pre-mRNAs (Fig. 3), and it can be said to interact with RNAs promiscuously *in vitro* and *in vivo* because of the broad spectrum of transcripts that it binds (7, 51, 52). Recently, it was revealed that PRC2



**Fig. 2. roX1 and roX2 RNAs are essential for the hyperactive *Drosophila* X chromosome.** The DCC consists of five proteins (gray) and roX1 or roX2 RNA (orange line). The MLE helicase remodels roX RNAs into a tandem stem-loop structure that is incorporated into a functional DCC. When fully assembled, this ribonucleoprotein complex is recruited to the X chromosome and acetylates Lys<sup>16</sup> on histone 4. This PTM results in chromosome decompression and hyperactive transcription. H4K16 acetylation of the X chromosome does not occur in the absence of roX RNA transcripts.



**Fig. 3. lncRNAs regulate transcription through histone modifiers.** PRC1 interacts with lncRNA, either TUG1 or MALAT1. These interactions regulate methylation status and localization of PRC1. PRC2 is inhibited by binding lncRNA or nascent pre-mRNA. lncRNAs Kcnq1ot1, Air, and ROR (regulator of reprogramming) regulate the activity of G9a, an enzyme that methylates H3K9. HOTTIP interacts with the WDR5-MLL complex and localizes the complex to the 5'HOXA locus. RNAPII, RNA polymerase II; MALAT1, metastasis-associated lung adenocarcinoma transcript 1.

reads RNA motifs consisting of short repeats of consecutive guanines, which are ubiquitous in the transcriptome (53); this clarifies the promiscuous nature of PRC2 targeting to RNA.

One important biological system involving PRC2 and lncRNAs is X-chromosome inactivation (XCI). As described in the previous section, female mammalian cells inactivate one of their two X chromosomes to equalize X-linked gene expression with that of males. One chief mediator of XCI is the 17-kb lncRNA *Xist* (X-inactive specific transcript), which is transcribed from the *Xist* gene on one X chromosome (54). Although the *Xist* RNA is capped, spliced, and polyadenylated, it remains exclusively in the nucleus and coats one X chromosome in cis. This RNA coating initiates XCI, coinciding with the exclusion of RNA Pol II and the eventual silencing of most gene expression on that X chromosome. One of the first histone modifications detected on the inactive X chromosome is H3K27me<sub>3</sub>, which is dependent on PRC2. The possibility that *Xist* RNA might directly recruit PRC2 has been much discussed (55, 56). A knockout of EED (embryonic ectoderm development) does not affect random XCI in the mouse embryo, suggesting that PRC2 may be dispensable for the initiation and maintenance of random XCI (57).

Recent studies have provided intriguing evidence for indirect recruitment of PRC2. McHugh and colleagues (58) identified RNA binding proteins associated with *Xist* RNA by ultraviolet (UV) cross-linking followed by purification and quantitative mass spectrometry (RAP-MS). Strikingly, the top hit was not PRC2, but instead three factors: SHARP/Spen, SAF-A, and LBR. In brief, subsequent work discovered that SHARP/Spen binds directly to *Xist* RNA and recruits the SMRT (silencing mediator of retinoid and thyroid receptor)–histone deacetylase 3 (HDAC3) complex. This leads to deacetylation of histone H3 and facilitates the enrichment of PRC2. As validation, the knockdown of SHARP and HDAC3 reactivates gene expression on the silenced X chromosome and leads to the depletion of PRC2. Another study used a similar approach but instead relied on formaldehyde cross-linking under non-denaturing conditions [chromatin isolation by RNA purification–mass spectrometry (ChIRP-MS)] (59). This study identified 81 proteins that directly or indirectly interact with *Xist*. Furthermore, the authors proposed that heterogeneous nuclear ribonucleoprotein K (hnRNPK) might have a direct influence on H3K27me<sub>3</sub> and Polycomb recruitment.

What is consistent between the two studies is that neither found components of PRC2 in the *Xist* RNA interactome. However, it is worthwhile to emphasize that another proteomics paper used an approach similar to that of McHugh *et al.* but came to a different conclusion (60). Specifically, they identified RBBP4/7 as possibly interacting with *Xist*. Although RBBP4 is a known subunit of the PRC2 complex, it is also a component of other chromatin-modifying complexes, including the NuRD and SIN3-HDAC complexes (61, 62). The study did not identify any of the core PRC2 subunits Ezh2, Suz12, and Eed.

Finally, two independent groups (63, 64) used elegant genetic screens to determine which genes are required for *Xist*-mediated XCI. Both groups identified the RNA binding protein Spen as the top hit. In total, these studies discovered dozens of new factors, each of which warrants further exploration in relation to *Xist* RNA function.

Beyond XCI, PRC2 has genome-wide roles. Another system that has received much attention in the field is HOTAIR lncRNA's interaction with PRC2. However, it has now been shown that HOTAIR is dispensable for the regulation of *Hoxd* transcription (65). Artificially tethering HOTAIR to chromatin does lead to an increase of H3K27me<sub>3</sub>, but in a PRC2-independent manner (66). Although it remains possible that lncRNAs recruit PRC2 to specific loci in some cases, currently, the

best-characterized function of RNAs is to inhibit PRC2 methyltransferase activity by inhibiting PRC2 binding to chromatin (67–69).

## OTHER HISTONE MODIFIERS

In recent years, the theme of lncRNAs controlling gene activity by mediating epigenetic mechanisms has become much more pervasive. Broadly, lncRNAs exercise the roles of recruiters, decoys, stimuli, and scaffolds, or some combinations thereof. This section will provide examples of lncRNAs driving gene regulation through the activity of chromatin modifiers. These recent studies establish that lncRNAs contribute to many biological systems. Understanding how these lncRNAs function, on the other hand, is challenging, and therefore, the mechanisms proposed require more validation and may be modified by future studies.

### G9a

G9a is a histone methyltransferase that deposits repressive methyl marks on H3K9. Its essential role is highlighted by lethality and severe growth defects observed in G9a-deficient embryos (70). It has been suggested that G9a targets transcriptionally active euchromatin regions, as opposed to repressive pericentric heterochromatin. G9a targeting has been associated with the regulation of genes important to development (71).

Three lncRNAs—*Kcnq1ot1*, *Air*, and *ROR*—have been suggested to interact with G9a via either the recruitment model or decoy model. *Kcnq1ot1* is a 91-kb transcript, transcribed from the antisense strand of the *Kcnq1* gene by RNA Pol II (72). It is exclusively localized in the nuclear compartment with moderate stability. In a ChIRP study, *Kcnq1ot1* was shown to interact with chromatin. Additional RIP experiments used antibodies raised against G9a to pull out *Kcnq1ot1* in a lineage-specific manner. This is consistent with a lineage-specific difference in the H3K9me<sub>3</sub> modification in the *Kcnq1* gene. The G9a-*Kcnq1ot1* interaction also contributes to imprinting in the mouse placenta. A similar recruiting mechanism has been observed with *Air* lncRNAs, which are largely unspliced and retained in the nucleus. It has been shown that *Air* is involved in silencing clusters of multiple imprinted genes in cis on chromosome 17 in mice (73). This silencing mechanism involves *Air* recruiting G9a to the paternal *Slc22a3*.

In the case of lncRNA *ROR*, it has been demonstrated that *ROR* evicts G9a. Human *ROR* is 2.6 kb in length, and true to its name, it functions by reprogramming human induced pluripotent stem cells (iPSCs) and shares regulatory miRNAs with the transcription factors OCT4, SOX2, and NANOG. Fan *et al.* (74) show that *ROR* occupies and activates the *TESC* promoter by repelling the histone G9a methyltransferase and promoting the release of histone H3K9 methylation. This decoying mechanism leads to a reduction in tumor growth and metastasis.

### Mixed lineage leukemia

MLL (mixed lineage leukemia) is a protein first identified as a functional ortholog of the trithorax (*trx*) complex in *Drosophila* (75). The canonical role of the MLL protein is to methylate H3K4, a trigger of gene activation. MLL has been shown to be required for the maintenance of activated genes during normal embryogenesis, hematopoiesis, and neurogenesis (76–78). The essentiality of MLL is underscored by the embryonic lethality of *MLL*-knockout mice.

How MLL might be recruited to specific genomic loci still remains to be fully elucidated. However, one study has shed light on a possible

mechanism involving a lncRNA called HOTTIP (79, 80), which appears to play a role in the trafficking of MLL to specific HOXA genes. Specifically, Wang and colleagues show that HOTTIP interacts with the WDR5-MLL complex and localizes the complex to the 5'HOXA locus. Quite remarkably, a follow-up investigation identified a single residue (F266) on WDR5 that is necessary for RNA binding and indispensable for gene activation. A similar mechanism has been proposed with the lncRNA HoxBlinc (81), which recruits the Set1/MLL complex. This recruitment is followed by the transcriptional activation of the *Hoxb* gene, thus regulating cardiac/hematopoietic differentiation. These studies together highlight the profound role of lncRNA binding in the regulation of active chromatin states.

Another compelling aspect of the scaffold-like property of some lncRNAs is the ability of a single transcript to bind multiple chromatin-modifier complexes. For instance, the Fendrr lncRNA is specifically expressed in the nascent lateral mesoderm in a developing embryo and has been reported to interact with both MLL and PRC2 complexes (82). Fendrr targets complexes to specific promoters to alter the epigenetic landscape. These epigenetic changes lead to attenuation of the expression of transcription factors, which are important in lateral mesoderm development. Therefore, as knowledge about the factors binding lncRNAs increases, it will become important to begin investigating how different factors engage in functional cross-talk.

### Heterochromatin protein 1

Heterochromatin protein 1 (HP1) was first characterized in *Drosophila* as localizing to heterochromatin and being involved in position-effect variegation (83, 84). HP1 binds methyl marks on H3K9 and elicits chromatin packaging and gene silencing. Early embryonic lethality in *Drosophila* is caused by the loss of HP1. In humans, the loss of HP1 has been shown to correlate with metastatic breast cancer (85).

The HP1 protein contains a conserved N-terminal chromodomain, followed by a variable hinge region, and finally a conserved chromoshadow domain at the C terminus. The chromodomain has been suggested to be an RNA binding module; for example, the MOF histone acetyltransferase (HAT) in *Drosophila* (described above) specifically interacts with roX RNA via its chromodomain (39), and these protein-RNA interactions may contribute to the recruitment of MOF to the X chromosome in male *Drosophila*. Evolutionarily, HP1's chromodomain shares homology to the MOF variant; therefore, it has been speculated that RNA acts similarly to recruit HP1 to pericentromeric loci. One early study found that the RNase treatment of cells induces dispersion of HP1 from the pericentromeric foci (86). Furthermore, replenishing RNase-treated cells with purified nuclear RNA rescues the pericentric structures. Later, it was shown that HP1 directly binds nuclear RNA using the electrophoretic mobility shift assay (EMSA). These early studies collectively suggested that the mechanism of HP1-mediated chromatin compaction in cells involves RNA actors. However, they did not offer a functional connection between specific RNAs and HP1.

In 2011, Maison and colleagues (87) reported that strand-specific centromeric RNAs (transcribed in the forward direction) colocalize with HP1 in mouse cells. Using HP1 chromatin immunoprecipitation (ChIP) experiments, it was observed that HP1 is enriched at the genomic regions encoding the centromeric RNAs. This study helped confirm a particular link between the subnuclear localization of RNA transcripts and HP1 recruitment. Maison *et al.* also revealed that the posttranslational SUMOylation of HP1 actively promotes binding of the protein to the purine-rich sense RNA transcripts, and the

combinatorial effects of SUMO and RNA binding together initiate targeting of HP1 to pericentric heterochromatin. This work reveals how PTMs of chromatin readers and remodelers might regulate their intrinsic binding properties and, subsequently, recruitment.

In addition to RNA having a recruitment role that captures free HP1 to pericentric heterochromatin, an antagonizing "eviction" role of lncRNA has also been proposed. One such study has identified a lncRNA called BORDERLINE in *Schizosaccharomyces pombe* (88), which, when processed into short RNAs, evicts HP1 and prevents the spreading of HP1 and histone H3K9 methylation beyond the pericentromeric repeat region.

### Suv4-20h

At pericentric and telomeric regions of chromosomes, heterochromatin formation is orchestrated by a series of interactions involving Suv39h, HP1, and Suv4-20h. Current literature shows that Suv39h methylates H3K9, which serves as a precursor to binding of HP1. Upon binding of methylated H3K9, HP1 recruits Suv4-20h by direct protein-protein interaction. Then, Suv4-20h proceeds to establish H4K20me3 marks. Alternative ways of targeting Suv4-20h to H4K20 have been proposed. One study provides evidence implicating lncRNA in this mechanism. Specifically, pre-ribosomal RNA (rRNA) antisense transcripts (PAPAS) bind pre-rRNA coding regions and recruit Suv4-20h2 in quiescent cells (89). This recruitment promotes H4K20me3-mediated transcriptional silencing of ribosomal DNA (rDNA). In addition, the authors observed a similar scheme at retrotransposon elements, where lncRNA triggers H4K20me3 and transcriptional repression.

### Polycomb repressive complex 1

PRC1 has a core that consists of four proteins: Bmi1, HPH, Ring1, and CBX. The chromodomain of CBX binds to trimethylated histone H3 Lys<sup>27</sup> and initiates the direct catalysis of H2A119 ubiquitination. These ubiquitination marks have been thought for years to recruit PRC2 in hierarchical fashion and subsequently enforce gene silencing and chromatin compaction. However, recent studies have provided alternative models that reveal emerging roles for PRC1. Details can be found in the review by Gil and O'Loughlen (90).

Regarding PRC1, an early study by Bernstein and colleagues (91) suggested that CBX proteins bind RNAs *in vitro*. Around 2010, two more studies provided mechanistic insights into the functional connections between lncRNA and CBX proteins. In particular, the antisense lncRNA ANRIL, which is transcribed from the *INK4b/ARF/INK4a* tumor suppressor locus, recruits PRC1 to that specific locus for transcriptional repression via a direct interaction with the CBX7 subunit. This repression regulates senescence and proliferation of prostate cancer cells. The authors observed a possible ternary complex consisting of H3K27me3-ANRIL-CBX7 (92).

Another CBX subunit of PRC1 that binds lncRNA is CBX4. Some lncRNA transcripts known to interact with CBX4 include TUG1 and MALAT1/NEAT2. These CBX4-RNA interactions stimulate the SUMOylation of the E2F1 growth factor (93), a PTM that results in increased cellular proliferation. Intriguingly, the methylation status of CBX4 appears to dictate whether CBX4 interacts with TUG1 or MALAT1/NEAT2, with the unmethylated variant binding the latter. Given that TUG1 and MALAT1/NEAT1 exhibit differential subnuclear localization, with TUG1 being localized to Polycomb bodies (PcGs) and MALAT1/NEAT2 located in interchromatin granules (ICGs), the methylation status of CBX4 can therefore dictate where PRC1 traffics in the subnuclear environment. This work provides a

clear example of how lncRNAs can act as scaffolds to organize nuclear architecture and influence recruitment of chromatin-modifier complexes.

### p300/CBP

p300 and CBP [cyclic adenosine monophosphate response element-binding protein (CREB)-binding protein] are two highly homologous and conserved proteins that have intrinsic HAT activity, which plays a critical role in regulating gene expression through lysine acetylation of histone H3 (94). These proteins act as transcriptional coactivators for a number of nuclear genes. Unlike other HATs, p300 and CBP are able to acetylate all four histones both *in vitro* and *in vivo* (95). Therefore, they are capable of coupling with a variety of transcription factors during chromatin remodeling. Not surprisingly, they are involved in a wide array of basic cellular processes, such as DNA damage repair and cell proliferation, and are inherently crucial for embryonic development and cancer.

For the first time in 2015 (96), p300 and CBP were implicated to interact with lncRNA. The study presents a fascinating model where the antisense lncRNA *Khps1* forms a DNA/RNA triplex with the *SPHK1* promoter, and these triplexes recruit CBP/p300. This recruitment triggers an open chromatin structure, followed by binding of transcription factors, and eventually leads to the activation of *SPHK1* transcription.

Recently, a genome-wide analysis of p300/CBP binding to RNA using PAR-CLIP (photoactivatable ribonucleoside-enhanced cross-linking and immunoprecipitation) was published (97). Bose and colleagues suggest that RNA transcribed locally directly interacts with CBP and stimulates catalytic HAT activity, thereby promoting gene expression. They also suggest that eRNAs at enhancers may interact with p300/CBP and control transcription activation.


### Lysine-specific demethylase 1

Lysine-specific demethylase 1 (LSD1) is a protein responsible for removing mono- and dimethyl modifications from H3K4 and H3K9 of histones, and it plays a pivotal role during embryonic development and cancer (98). This is highlighted by a variety of tumors that display LSD1 overexpression (99). LSD1 is the first identified histone demethylase and has been found to associate with a number of transcriptional corepressor complexes (including CoREST and CtBP) and a subset of HDAC complexes (99). The lncRNA *HOTAIR*, transcribed from the *HoxC* locus, has been reported to interact with LSD1 and also with PRC2 (100). This illustrates the scaffold-like function of some lncRNAs, which has been studied in detail in the case of yeast *TR* (101).

Curiously, the TERRA (telomeric repeat-containing RNA) RNA transcribed from telomeres has been shown to interact with LSD1. TERRA is bound by LSD1 at TRF2-depleted telomeres, and the RNA promotes the physical interaction between LSD1 and MRE11 (102). This physical interaction stimulates MRE11 nuclease activity and consequently stimulates removal of 3'G-strand overhangs at uncapped telomeres.

### DNA METHYLTRANSFERASES

DNA methylation is widely involved in transcriptional repression in mammals, with DNA methyltransferases (DNMTs) methylating cytosines (m<sup>5</sup>C) in CpG-rich sequences. Growing evidence has demonstrated that all three major DNMTs (DNMT1, DNMT3A, and DNMT3B) in mammals bind to and can be regulated by noncoding RNAs. This regulation by noncoding RNAs usually results in alteration of DNA methylation and expression of target genes (Fig. 4). DNMT2, the enigmatic DNMT homolog, has little DNA methylation activity but instead methylates transfer RNAs (tRNAs) (103, 104), and this could imply that the RNA binding properties of DNMTs have a deep evolutionary origin.



**Fig. 4. ncRNAs regulate transcription through DNA binding proteins.** lncRNAs (and sometimes miRNAs) interact with DNMTs, resulting in recruitment or inhibition of DNMTs at chromatin loci. Alteration of DNA methylation (m<sup>5</sup>C) level generally affects local transcription. lncRNA–transcription factor interactions can either recruit or evict transcription factors from chromatin, and this action can be either *in cis* (demonstrated in figure) or *in trans*. eRNA transcribed from an enhancer region can contribute to chromatin looping and gene activation. lncRNAs interact with the chromatin insulator CCCTC-binding factor (CTCF) and regulate transcription. The mechanism may involve CTCF's action in chromatin looping and nuclear architecture. TSS, transcription start site.

### DNA methyltransferase 1

DNMT1 is the key maintenance DNMT and is ubiquitously expressed in proliferating cells. A few RNAs have been identified to regulate the activity of DNMT1. *Kcnq1ot1*, a lncRNA that regulates the *Kcnq1* imprinting control region (105), interacts with and recruits DNMT1 to differentially methylated regions (106). However, whether the interaction between DNMT1 and *Kcnq1ot1* lncRNA is direct or indirect is unclear because of the limitation of RIP experiments, as discussed earlier in this review.

Later, a noncoding RNA named *ecCEBPA* arising from the *CEBPA* (CCAAT/enhancer-binding protein  $\alpha$ ) gene locus was found to interact with DNMT1, resulting in decreased methylation at the *CEBPA* gene (107). Surprisingly, in this study, DNMT1 bound to RNA with a greater affinity than to its own substrate DNA *in vitro*, and DNMT1 seemed to prefer binding with stem loop–structured RNAs. This study also provided mutagenesis scanning of the DNMT1 protein and suggested that the catalytic domain is the minimal RNA binding motif. DNMT1-RNA interaction is not limited to the *CEBPA* locus, and RNA species associated with DNMT1 and their regulation of DNA methylation and gene expression have been globally identified, indicating that RNA could block unwanted DNA methylation at many sites of active transcription.

Moreover, two later studies supported the inhibition model. A lncRNA named *DBCCR1-003* binds to DNMT1 and prevents DNMT1-mediated methylation of *DBCCR1* in bladder cancer (108), and lncRNA *RBMY2FP* interacts with DNMT1 and hampers its binding to promoters of the *RBMY* gene family (109). Besides lncRNAs, miRNAs including *miR-155-5p* also bind to and inhibit DNMT1 *in vitro* and *in vivo* (110), suggesting a widespread role of RNA interaction in regulating the activity of DNMT1.

### DNA methyltransferase 3A

DNMT3A and DNMT3B are the *de novo* DNMTs and show no preference between hemimethylated and unmethylated DNA substrates (111, 112). *Tsix* RNA (the antisense of *Xist*) can form a complex with DNMT3A, as demonstrated by an RNA-ChIP analysis, but not with DNMT1, DNMT2, or DNMT3B (113). *Tsix* RNA might activate DNMT3A at the *Xist* promoter and repress the *Xist* gene. The molecular details of the DNMT3A-RNA interaction were later demonstrated *in vitro* as two modes: allosteric regulation (no change in catalysis) and catalytic domain binding (potent inhibition) (114), supporting a model that the molecular basis of the DNMT3A-RNA interaction determines the effects on DNA methylation activity of DNMT3A.

### DNA methyltransferase 3B

DNMT3B can be recruited by a DNA/RNA triplex, formed by a noncoding RNA [promoter-associated RNA (pRNA)] and the rDNA promoter region (115). DNMT3B, but not DNMT1 or DNMT3A, shows a preference for DNA/RNA triplexes *in vitro*, suggesting a potentially widespread RNA-guided DNMT3B targeting mechanism in epigenetic regulation.

## TRANSCRIPTION FACTORS

Transcription factors are sequence-specific DNA binding proteins that can activate or repress transcription. Growing evidence suggests that a large number of transcription factors interact with RNA, and these interactions could play an important role in their regulation [Fig. 4; also reviewed by Hudson and Ortlund (8)]. A classic example is the

feedback inhibition of zinc finger protein transcription factor IIIA (TFIIIA) by 5S rRNA. TFIIIA activates 5S rRNA transcription in *Xenopus* oocytes, and increasing levels of the 5S rRNA products strip TFIIIA off chromatin (116–120). Similar to this inhibition mechanism, *GAS5* lncRNA acts as a decoy RNA by binding to the DNA binding domain of glucocorticoid receptor (GR), inhibiting GR's DNA binding and transcriptional activation activity (121).

In contrast to the inhibition and decoy mechanism, RNA can also activate or recruit transcription factors. YY1 is a ubiquitous transcription factor that can activate or repress individual promoters. In mammals, X-chromosome inactivation requires the interaction between YY1 and *Xist* lncRNA. YY1 interacts with the Repeat C region of *Xist* RNA and contributes to docking *Xist* RNA onto the X chromosome (122). YY1 binds to both gene regulatory elements and their associated RNA species (transcribed from the same regulatory elements) across the entire genome, and artificial tethering of RNA enhances YY1 occupancy at these elements, potentially providing a positive feedback for robust transcription (123). A lncRNA transcribed from the YY1 gene promoter (*linc-YY1*) interacts with YY1 through its middle domain to evict YY1-PRC2 from target promoters, thus activating gene expression *in trans* (124). A recent SELEX (systematic evolution of ligands by exponential enrichment) study found that YY1 interacts with RNA with low sequence specificity (125), and the lack of RNA sequence specificity has been commonly observed among chromatin binders more generally. The biochemical and structure nature of the protein-RNA interaction may determine the inhibition or activation mechanism. If the DNA and RNA binding are shared as in the cases of TFIIIA and GR, then an inhibition mechanism is more likely to be used. Otherwise, the inhibition mechanism may apply when the DNA and RNA binding are mutually exclusive as for YY1 (123).

Besides these well-studied interactions, an increasing number of lncRNAs have been demonstrated to regulate transcription through transcription factors. A lncRNA transcribed from the *CDKN1A* promoter, *PANDA*, differentially interacts with the transcription factor NF-YA (nuclear transcription factor Y subunit alpha) or PRCs (PRC1 and PRC2) to either promote or suppress senescence (126). The lncRNA rhabdomyosarcoma 2–associated transcript (RMST) interacts directly with SOX2 protein to activate gene expression, and chromatin occupancy of SOX2 was reduced following RMST depletion (127, 128). A few other examples are listed in Table 1. Most of the lncRNA–transcription factor interactions have been demonstrated by RIP experiments, so indirect versus direct interactions could not be differentiated. Identification of the RNA binding motif in the protein and the corresponding RNA identity element would be helpful to confirm these interactions.

A few other studies infer roles of lncRNAs in regulating transcription factor activities, although no direct physical interaction was reported. For example, the *NRON* lncRNA forms a complex with a few other proteins to repress the transcription factor NFAT (nuclear factor of activated T cell), potentially by regulating NFAT's subcellular localization (129). Future *in vitro* EMSA or *in vivo* pull-down experiments would be helpful to identify these interactions.

## OTHER DNA BINDING TRANSCRIPTION REGULATORS

### CCCTC-binding factor

CTCF is a ubiquitous zinc finger protein that binds DNA and serves as a chromatin insulator, activator, or repressor, depending on the epigenetic

**Table 1. Transcription factors and their interacting RNAs.** N/A, not applicable; PVT1, plasmacytoma variant translocation 1; HSF1, heat shock factor 1; HSR1, heat shock RNA 1; DHFR, dihydrofolate reductase; ICR1, interfering Crick RNA 1; PWR1, promoting Watson RNA 1.

| Transcription factor | RNA binder  | Evidence of interaction                   | Function of interaction   | References              |
|----------------------|---|---|---|-------------------------|
| YY1                  | Xist, linc-YY1, and gene regulatory element-associated RNAs | RIP, EMSA, and in vivo tethering          | YY1 helps to tether Xist RNA to the inactive X nucleation center; YY1 trapping by lincRNA for robust activation | (122) (123) (124) (125) |
| NFAT                 | NRON noncoding RNA  | N/A                                       | Represses NFAT  | (129)                   |
| NF-YA                | PANDA lincRNA   | RNA pull down                             | Attenuates NF-YA's occupancy at target gene promoters   | (126)                   |
| SOX2                 | RMST lincRNA  | RIP                                       | Activates gene transcription  | (127, 128)              |
| MYC                  | PVT1 lincRNA  | Genetic disruption                        | Prevents phosphorylation and degradation of MYC   | (160)                   |
| TFIIIA               | 5S rRNA   | Mutagenesis, binding assays               | Regulates TFIIIA activity   | (116–120)               |
| TFIIB                | DHFR upstream transcripts                                   | EMSA and RIP                              | Dissociates the preinitiation complex from the major promoter   | (161)                   |
| HSF1                 | HSR1 lincRNA  | In vitro activation assay and in vivo RIP | Activates HSF1  | (162)                   |
| Flo8 and Sfl1        | ICR1 and PWR1 lincRNAs                                      | Genetic disruption and ChIP analysis      | Dictates the variegated expression of FLO11 mRNA in yeast   | (149, 163)              |
| PURB                 | linc-HOXA1 RNA  | RIP                                       | Represses Hoxa1 by recruiting PURB as a transcriptional cofactor  | (164)                   |

context [reviewed by Ong and Corces (130) and Phillips and Corces (131)]. CTCF was first demonstrated to interact with RNA in the initiation of XCI (132). CTCF represses Xist expression by binding to its promoter and is later titrated away from the Xist promoter by Jpx RNA when XCI is initiated. The interaction between CTCF and Xist is supported by in vivo UV-crosslinked RIP (UV-RIP) and in vitro gel shift assays.

Later, a number of lincRNAs were found to regulate CTCF and affect transcription. CTCF forms a complex with DEAD-box RNA helicase p68 (DDX5) and an associated noncoding RNA, steroid receptor RNA activator (SRA), and this complex may be essential for CTCF's insulator function (133). In another study, CTCF was found to regulate p53 expression through its physical interaction with Wrap53 RNA, and an RNA binding region (residues 576 to 614) of CTCF was identified by in vitro scanning mutagenesis (134). This study also discovered that CTCF interacts with a variety of RNAs in vivo using a PAR-CLIP experiment. A later study further confirmed the observation that CTCF binds thousands of transcripts in vivo in mouse embryonic stem cells, including Tsix, Xite, and Xist RNAs, many in close proximity to CTCF's genomic binding sites (135). The function of the RNP formed by CTCF in XCI was further expanded by a study demonstrating that lincRNA Firre (functional intergenic repeating RNA element) colocalizes with CTCF on the X chromosome, although no evidence for direct interaction was presented (136). A mutagenesis study of CTCF and one of its RNA binders—MYCNOS lincRNA—implicated zinc fingers 9 to 11 (500 to 576 amino acids) of CTCF and exons 1 and 3 of MYCNOS lincRNA as the crucial interacting regions (137).

### **$\alpha$ -Thalassemia/mental retardation X-linked**

$\alpha$ -Thalassemia/mental retardation X-linked (ATRX) is a transcriptional regulator that belongs to the SWI/SNF (switch/sucrose nonfermentable) family of chromatin remodeling proteins. It has ATPase activity that is stimulated by naked DNA and mononucleosomes (138, 139) and also has a DNA translocase activity (139, 140). In a more recent study, ATRX was unexpectedly found to function as a high-affinity RNA binding protein,

which directly interacts with RepA/Xist RNA to promote loading of PRC2 in vivo (141). Interaction between ATRX and Xist RNA is supported by UV-RIP analysis and in vitro gel shift assays, and a minimal RepA region on Xist has been identified as the specific identity element (141). Although ATRX seems to be able to bind to both double-stranded DNA (dsDNA) and RNA with similar affinities and probably using different regions of the protein, an RNA-ATRX-dsDNA ternary complex was not detected using a pull-down experiment. Furthermore, a separation-of-function mutant of ATRX that still binds DNA but no longer binds RNA would be useful to confirm the importance of RNA binding in XCI. In addition, ATRX is also related to the function of TERRA lincRNA [reviewed by Rippe and Luke (142)], but a direct interaction has not been demonstrated.

### **Distal-less homeobox 2**

Homeobox protein DLX2 (distal-less homeobox 2) is a DNA binding transcription regulator. EVF2 lincRNA is a transcriptional coactivator of DLX2 and recruits methyl-CpG-binding protein 2 (MECP2) to intergenic enhancers. A direct interaction between DLX2 and EVF2 has been demonstrated by the immunoprecipitation of DLX2, followed by reverse transcription polymerase chain reaction of the EVF2 lincRNA, and is supported by their intranuclear colocalization (143, 144). A conserved region of EVF2 has been shown to be important for the interaction with DLX2, and the interaction is important in maintaining the transcriptional activity of the DLX5/6 enhancer.

### **THE IMPACT OF TRANSCRIPTION ITSELF**

It has also been shown that the act of transcription, rather than the RNA product of transcription, can have regulatory effects on neighboring loci in the mammalian nucleus. Numerous groups have recently reported on this phenomenon. One group found that transcription of the mouse noncoding *Airn* gene leads to silencing of the overlapping *Igf2r* gene in mice, but the Air lincRNA product is not required (145). Another



study found that genetically disrupting transcription at both lncRNA and protein-coding loci was sufficient to dysregulate the expression of neighboring genes (146). An additional report discovered an essential interplay between the heart development gene *HAND2* and active transcription of an upstream lncRNA termed *upperhand* (*Uph*) (147). The researchers found that disrupting *Uph* transcription abolished *Hand2* expression, whereas knockdown of the mature *Uph* transcript had no effect (147).

These observations were presaged by studies in budding yeast. For example, transcriptional repression of the *SER3* gene depends on active transcription of nearby noncoding sequences, which interferes with the binding of activators to the *SER3* promoter (148). In another case, two yeast lncRNAs transcribed in opposite directions provide a “toggle switch” that can either repress or activate the transcription of an adjacent protein-coding gene (149). Thus, in general, many lncRNAs may function not at the RNA level, but rather simply because they are transcribed, and this transcription can lead to activation or repression of nearby genes.

### **lncRNAs ORGANIZING NUCLEAR ARCHITECTURE**

There are several prominent examples of lncRNAs acting as platforms for nuclear organization [reviewed by Melé and Rinn (150)]. One well-studied example is *NEAT1*, a lncRNA that is sufficient to generate nuclear paraspeckles (150, 151). Recently, a lncRNA, termed *Firre*, was identified as essential for adipocyte differentiation, and it displays a unique function in nuclear organization (136, 152, 153). Genetic deletion studies of *Firre* in embryonic stem cells showed that the lncRNA interacts with hnRNPU and mediates cross-chromosomal contacts between five chromosomes (153). Knockout of the transcript had no effect on the expression of the neighboring genomic loci (153). Additionally, oligonucleotide-mediated knockdown of this transcript was shown to dysregulate a myriad of RNA processing genes (154).

### **LOOKING INTO THE FUTURE, WHAT KINDS OF EXPERIMENTS ARE NEEDED TO ESTABLISH MECHANISM?**

Many published studies show an association between a lncRNA and transcriptional repression or activation. A reasonable next question to ask is whether the association is causative; establishing causation requires perturbing the production, stability, nucleotide sequence, or cellular location of the lncRNA and observing a concomitant change in expression of specific gene(s). This set of experiments provides the starting point for understanding mechanism; that is, how does the lncRNA perform its function?

In considering mechanisms, we start with cases in which a lncRNA represses transcription. One possibility is that the lncRNA acts as a “sponge” or “decoy,” binding a transcription-activating protein and preventing it from associating with its DNA or RNA target. Deciding whether this mechanism is tenable requires measuring the stoichiometry of the lncRNA relative to the protein and the relative affinity of the protein for the lncRNA versus the target nucleic acid. For example, a lncRNA present at 100 copies per cell is unlikely to provide an efficient sponge for a transcriptional protein present at 10,000 copies per cell, unless there is some special compartmentalization. A related possibility is that RNA binding functionally inactivates the protein. For example, if a transcriptional regulatory protein binds its DNA target and a lncRNA at the same site (or mutually exclusively), then

the mechanism of lncRNA inhibition is clear. Mutually exclusive binding can be tested, for example, by competition binding experiments (155) or by determining cocrystal structures of the protein-DNA and protein-lncRNA complexes (8).

We next consider cases in which the lncRNA activates transcription. One possible mechanism involves the lncRNA recruiting an activating protein to its site of action. To establish this mechanism, one must first find the sequences and/or structures on the lncRNA that bind the protein, for example, using motif searching, mutagenesis, and protein-RNA footprinting. If transcriptional activation occurs in *cis*, then binding to nascent transcripts may, by itself, accomplish recruitment. However, if activation is occurring in *trans*, then establishing the protein-lncRNA binding is only half the story, and one must next ask how the lncRNA facilitates recruitment. The three most obvious possibilities are (i) the lncRNA binds to a protein bound at the target locus, (ii) the lncRNA base pairs to nascent transcripts at the target locus, or (iii) the lncRNA binds directly to the DNA at the target locus by triplex formation or potentially R-loop formation. In cases where intermolecular RNA-RNA base pairing is implicated, the observation of sequence complementarity is insufficient to indicate pairing. Convincing evidence can be obtained by introducing mutations that disrupt pairing and compensatory second-site mutations and by psoralen photocrosslinking (156).

Another potential function of lncRNAs is to act as a scaffold, bringing proteins together in an RNP complex. In the simplest cases, the RNA will have individual sequence and structure motifs, each of which binds a single protein or protein complex. If the only function of the lncRNA is to act as a scaffold, then deletion of a protein binding motif will result in loss of function, but reinsertion of that motif at an unnatural location within the RNA will restore function (157).

Finally, how does one test the hypothesis that active transcription of noncoding sequences, rather than the lncRNA product of this transcription, controls the expression of another gene(s)? As has been discussed by Bassett *et al.* (158), this is particularly challenging. Deletion of the promoter for the lncRNA [for example, by CRISPR (clustered regularly interspaced short palindromic repeats)–Cas9 genome editing] is often too crude of an approach, because the deletion may remove DNA elements that regulate the transcription of a proximal mRNA gene (146). Inserting multiple polyadenylation sequences downstream from a lncRNA promoter and interfering with lncRNA transcription using CRISPR interference (159) are more surgically incisive, but negative results must be interpreted with caution because these techniques truncate rather than eliminate lncRNA transcription. Replacing a lncRNA sequence with a different sequence without functional consequence does not necessarily indicate that the lncRNA is unimportant, given the fact that many histone-modifying complexes bind RNA promiscuously and thus might still bind the substituted sequence. Moreover, knockdown of the lncRNA product with antisense nucleic acids (Gapmers) that function in the nucleus may suggest the unimportance of the lncRNA product, but unlike genome editing, these knockdowns are incomplete. Thus, it is best to use multiple approaches when assessing whether it is the act of transcription or the lncRNA product that is functional in any particular instance.

In conclusion, the era of cataloging mammalian and other eukaryotic lncRNAs is well under way. Researchers are determining their tissue distribution, subcellular localization, expression patterns, abundance, and splicing patterns, which requires enormous effort but is reasonably straightforward. The era of determining the function of these lncRNAs, on the other hand, is just beginning.

## REFERENCES AND NOTES

- S. J. Liu, M. A. Horlbeck, S. W. Cho, H. S. Birk, M. Malatesta, D. He, F. J. Attenello, J. E. Villalta, M. Y. Cho, Y. Chen, M. A. Mandegar, M. P. Olvera, L. A. Gilbert, B. R. Conklin, H. Y. Chang, J. S. Weissman, D. A. Lim, CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. *Science* **355**, eaah7111 (2017).
- W. Li, D. Notani, M. G. Rosenfeld, Enhancers as non-coding RNA transcription units: Recent insights and future perspectives. *Nat. Rev. Genet.* **17**, 207–223 (2016).
- T. R. Cech, J. A. Steitz, The noncoding RNA revolution—Trashing old rules to forge new ones. *Cell* **157**, 77–94 (2014).
- B. Lemieux, N. Laterreur, A. Perederina, J.-F. Noël, M.-L. Dubois, A. S. Krasilnikov, R. J. Wellinger, Active yeast telomerase shares subunits with ribonucleoproteins RNase P and RNase MRP. *Cell* **165**, 1171–1181 (2016).
- D. G. Hendrickson, D. R. Kelley, D. Tenen, B. Bernstein, J. L. Rinn, Widespread RNA binding by chromatin-associated proteins. *Genome Biol.* **17**, 28 (2016).
- X. Wang, J. C. Schwartz, T. R. Cech, Nucleic acid-binding specificity of human FUS protein. *Nucleic Acids Res.* **43**, 7535–7543 (2015).
- C. Davidovich, L. Zheng, K. J. Goodrich, T. R. Cech, Promiscuous RNA binding by Polycomb repressive complex 2. *Nat. Struct. Mol. Biol.* **20**, 1250–1257 (2013).
- W. H. Hudson, E. A. Ortlund, The structure, function and evolution of proteins that bind DNA and RNA. *Nat. Rev. Mol. Cell Biol.* **15**, 749–760 (2014).
- B. J. DiDomenico, G. E. Bugaisky, S. Lindquist, The heat shock response is self-regulated at both the transcriptional and posttranscriptional levels. *Cell* **31**, 593–603 (1982).
- R. C. Findly, T. Pederson, Regulated transcription of the genes for actin and heat-shock proteins in cultured *Drosophila* cells. *J. Cell Biol.* **88**, 323–328 (1981).
- D. S. Gilmour, J. T. Lis, In vivo interactions of RNA polymerase II with genes of *Drosophila melanogaster*. *Mol. Cell Biol.* **5**, 2009–2018 (1985).
- T. O'Brien, J. T. Lis, Rapid changes in *Drosophila* transcription after an instantaneous heat shock. *Mol. Cell Biol.* **13**, 3456–3463 (1993).
- W. M. Liu, W. M. Chu, P. V. Choudary, C. W. Schmid, Cell stress and translational inhibitors transiently increase the abundance of mammalian SINE transcripts. *Nucleic Acids Res.* **23**, 1758–1765 (1995).
- A. J. Fornace Jr., J. B. Mitchell, Induction of B2 RNA polymerase III transcription by heat shock: Enrichment for heat shock induced sequences in rodent cells by hybridization subtraction. *Nucleic Acids Res.* **14**, 5793–5811 (1986).
- V. V. Lunyak, G. G. Prefontaine, E. Núñez, T. Cramer, B.-G. Ju, K. A. Ohgi, K. Hutt, R. Roy, A. García-Díaz, X. Zhu, Y. Yung, L. Montoliu, C. K. Glass, M. G. Rosenfeld, Developmentally regulated activation of a SINE B2 repeat as a domain boundary in organogenesis. *Science* **317**, 248–251 (2007).
- T.-H. Li, J. Spearow, C. M. Rubin, C. W. Schmid, Physiological stresses increase mouse short interspersed element (SINE) RNA expression in vivo. *Gene* **239**, 367–372 (1999).
- D. A. Kramerov, N. S. Vassetzky, SINEs. *Wiley Interdiscip. Rev. RNA* **2**, 772–786 (2011).
- T. A. Allen, S. Von Kaenel, J. A. Goodrich, J. F. Kugel, The SINE-encoded mouse B2 RNA represses mRNA transcription in response to heat shock. *Nat. Struct. Mol. Biol.* **11**, 816–821 (2004).
- D. A. Kramerov, N. S. Vassetzky, Short retroposons in eukaryotic genomes. *Int. Rev. Cytol.* **247**, 165–221 (2005).
- C. A. Espinoza, T. A. Allen, A. R. Hieb, J. F. Kugel, J. A. Goodrich, B2 RNA binds directly to RNA polymerase II to repress transcript synthesis. *Nat. Struct. Mol. Biol.* **11**, 822–829 (2004).
- S. Mili, J. A. Steitz, Evidence for reassessment of RNA-binding proteins after cell lysis: Implications for the interpretation of immunoprecipitation analyses. *RNA* **10**, 1692–1694 (2004).
- K. M. Wassarman, G. Storz, 6S RNA regulates *E. coli* RNA polymerase activity. *Cell* **101**, 613–623 (2000).
- C. A. Espinoza, J. A. Goodrich, J. F. Kugel, Characterization of the structure, function, and mechanism of B2 RNA, an ncRNA repressor of RNA polymerase II transcription. *RNA* **13**, 583–596 (2007).
- P. Yakovchuk, J. A. Goodrich, J. F. Kugel, B2 RNA and Alu RNA repress transcription by disrupting contacts between RNA polymerase II and promoter DNA within assembled complexes. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 5569–5574 (2009).
- H. Kettenberger, A. Eisenführ, F. Brueckner, M. Theis, M. Famulok, P. Cramer, Structure of an RNA polymerase II-RNA inhibitor complex elucidates transcription regulation by noncoding RNAs. *Nat. Struct. Mol. Biol.* **13**, 44–48 (2006).
- A. Zovoillis, C. Cifuentes-Rojas, H.-P. Chu, A. J. Hernandez, J. T. Lee, Destabilization of B2 RNA by EZH2 activates the stress response. *Cell* **167**, 1788–1802.e13 (2016).
- S. Rastan, X chromosome inactivation and the *Xist* gene. *Curr. Opin. Genet. Dev.* **4**, 292–297 (1994).
- R. L. Kelley, M. I. Kuroda, Equality for X chromosomes. *Science* **270**, 1607–1610 (1995).
- J. C. Lucchesi, Dosage compensation in *Drosophila* and the 'complex' world of transcriptional regulation. *BioEssays* **18**, 541–547 (1996).
- M. Rutenberg-Schoenberg, A. N. Sexton, M. D. Simon, The properties of long noncoding RNAs that regulate chromatin. *Annu. Rev. Genomics Hum. Genet.* **17**, 69–94 (2016).
- H. Amrein, R. Axel, Genes expressed in neurons of adult male *Drosophila*. *Cell* **88**, 459–469 (1997).
- V. H. Meller, B. P. Rattner, The *roX* genes encode redundant *male-specific lethal* transcripts required for targeting of the MSL complex. *EMBO J.* **21**, 1084–1091 (2002).
- A. Franke, B. S. Baker, The *rox1* and *rox2* RNAs are essential components of the compensosome, which mediates dosage compensation in *Drosophila*. *Mol. Cell* **4**, 117–122 (1999).
- R. L. Kelley, V. H. Meller, P. R. Gordadze, G. Roman, R. L. Davis, M. I. Kuroda, Epigenetic spreading of the *Drosophila* dosage compensation complex from *roX* RNA genes into flanking chromatin. *Cell* **98**, 513–522 (1999).
- V. H. Meller, K. H. Wu, G. Roman, M. I. Kuroda, R. L. Davis, *roX1* RNA paints the X chromosome of male *Drosophila* and is regulated by the dosage compensation system. *Cell* **88**, 445–457 (1997).
- E. R. Smith, A. Pannuti, W. Gu, A. Steurnagel, R. G. Cook, C. D. Allis, J. C. Lucchesi, The *drosophila* MSL complex acetylates histone H4 at lysine 16, a chromatin modification linked to dosage compensation. *Mol. Cell Biol.* **20**, 312–318 (2000).
- A. Akhtar, D. Zink, P. B. Becker, Chromodomains are protein-RNA interaction modules. *Nature* **407**, 405–409 (2000).
- E. Hallacii, A. Akhtar, X chromosomal regulation in flies: When less is more. *Chromosome Res.* **17**, 603–619 (2009).
- A. Akhtar, P. B. Becker, Activation of transcription through histone H4 acetylation by MOF, an acetyltransferase essential for dosage compensation in *Drosophila*. *Mol. Cell* **5**, 367–375 (2000).
- E. R. Smith, C. D. Allis, J. C. Lucchesi, Linking global histone acetylation to the transcription enhancement of X-chromosomal genes in *Drosophila* males. *J. Biol. Chem.* **276**, 31483–31486 (2001).
- I. A. Ilik, J. J. Quinn, P. Georgiev, F. Tavares-Cadete, D. Maticzka, S. Toscano, Y. Wan, R. C. Spitale, N. Luscombe, R. Backofen, H. Y. Chang, A. Akhtar, Tandem stem-loops in *roX* RNAs act together to mediate X chromosome dosage compensation in *Drosophila*. *Mol. Cell* **51**, 156–173 (2013).
- S. Maenner, M. Müller, J. Fröhlich, D. Langer, P. B. Becker, ATP-dependent *roX* RNA remodeling by the helicase maleless enables specific association of MSL proteins. *Mol. Cell* **51**, 174–184 (2013).
- A. Izzo, C. Regnard, V. Morales, E. Kremmer, P. B. Becker, Structure-function analysis of the RNA helicase maleless. *Nucleic Acids Res.* **36**, 950–962 (2008).
- J. R. Prabu, M. Muller, A. W. Thoma, S. Schüssler, F. Bonneau, P. B. Becker, E. Conti, Structure of the RNA helicase MLE reveals the molecular mechanisms for uridine specificity and RNA-ATP coupling. *Mol. Cell* **60**, 487–499 (2015).
- A. Buscaino, T. Köcher, J. H. Kind, H. Holz, M. Taipale, K. Wagner, M. Wilm, A. Akhtar, MOF-regulated acetylation of MSL-3 in the *Drosophila* dosage compensation complex. *Mol. Cell* **11**, 1265–1277 (2003).
- J. Kind, J. M. Vaquerizas, P. Gebhardt, M. Gentzel, N. M. Luscombe, P. Bertone, A. Akhtar, Genome-wide analysis reveals MOF as a key regulator of dosage compensation and gene expression in *Drosophila*. *Cell* **133**, 813–828 (2008).
- A. A. Alekseyenko, S. Peng, E. Larschan, A. A. Gorchakov, O.-K. Lee, P. Kharchenko, S. D. McGrath, C. I. Wang, E. R. Mardis, P. J. Park, M. I. Kuroda, A sequence motif within chromatin entry sites directs MSL establishment on the *Drosophila* X chromosome. *Cell* **134**, 599–609 (2008).
- T. Straub, C. Grimaud, G. D. Gilfillan, A. Mitterweger, P. B. Becker, The chromosomal high-affinity binding sites for the *Drosophila* dosage compensation complex. *PLoS Genet.* **4**, e1000302 (2008).
- F. Li, A. H. Schiemann, M. J. Scott, Incorporation of the noncoding *roX* RNAs alters the chromatin-binding specificity of the *Drosophila* MSL1/MSL2 complex. *Mol. Cell Biol.* **28**, 1252–1264 (2008).
- M. L. Soruco, J. Chery, E. P. Bishop, T. Siggers, M. Y. Tolstorukov, A. R. Leydon, A. U. Sugden, K. Goebel, J. Feng, P. Xia, A. Vedenko, M. L. Bulyk, P. J. Park, E. Larschan, The CLAMP protein links the MSL complex to the X chromosome during *Drosophila* dosage compensation. *Genes Dev.* **27**, 1551–1556 (2013).
- C. Davidovich, X. Wang, C. Cifuentes-Rojas, K. J. Goodrich, A. R. Gooding, J. T. Lee, T. R. Cech, Toward a consensus on the binding specificity and promiscuity of PRC2 for RNA. *Mol. Cell* **57**, 552–558 (2015).
- S. Kaneko, J. Son, S. S. Shen, D. Reinberg, R. Bonasio, PRC2 binds active promoters and contacts nascent RNAs in embryonic stem cells. *Nat. Struct. Mol. Biol.* **20**, 1258–1264 (2013).
- X. Wang, K. J. Goodrich, A. R. Gooding, H. Naem, S. Archer, R. D. Paucek, D. T. Youmans, T. R. Cech, C. Davidovich, Targeting of Polycomb repressive complex 2 to RNA by short repeats of consecutive guanines. *Mol. Cell* **65**, 1056–1067.e5 (2017).
- S. Augui, E. P. Nora, E. Heard, Regulation of X-chromosome inactivation by the X-inactivation centre. *Nat. Rev. Genet.* **12**, 429–442 (2011).

55. N. Brockdorff, Noncoding RNA and Polycomb recruitment. *RNA* **19**, 429–442 (2013).
56. C. Davidovich, T. R. Cech, The recruitment of chromatin modifiers by long noncoding RNAs: Lessons from PRC2. *RNA* **21**, 2007–2022 (2015).
57. S. Kalantry, T. Magnuson, The Polycomb group protein EED is dispensable for the initiation of random X-chromosome inactivation. *PLoS Genet.* **2**, e66 (2006).
58. C. A. McHugh, C.-K. Chen, A. Chow, C. F. Surka, C. Tran, P. McDonel, A. Pandya-Jones, M. Blanco, C. Burghard, A. Moradian, M. J. Sweredoski, A. A. Shishkin, J. Su, E. S. Lander, S. Hess, K. Plath, M. Guttman, The *Xist* lncRNA interacts directly with SHARP to silence transcription through HDAC3. *Nature* **521**, 232–236 (2015).
59. C. Chu, Q. C. Zhang, S. T. da Rocha, R. A. Flynn, M. Bharadwaj, J. M. Calabrese, T. Magnuson, E. Heard, H. Y. Chang, Systematic discovery of *Xist* RNA binding proteins. *Cell* **161**, 404–416 (2015).
60. A. Minajigi, J. E. Froberg, C. Wei, H. Sunwoo, B. Kesner, D. Colognori, D. Lessing, B. Payer, M. Boukhali, W. Haas, J. T. Lee, A comprehensive *Xist* interactome reveals cohesin repulsion and an RNA-directed chromosome conformation. *Science* **349**, aab2276 (2015).
61. M. D. Clark, R. Marcum, R. Graveline, C. W. Chan, T. Xie, Z. Chen, Y. Ding, Y. Zhang, A. Mondragón, G. David, I. Radhakrishnan, Structural insights into the assembly of the histone deacetylase-associated Sin3L/Rpd3L corepressor complex. *Proc. Natl. Acad. Sci. U.S.A.* **112**, E3669–E3678 (2015).
62. C. J. Millard, N. Varma, A. Saleh, K. Morris, P. J. Watson, A. R. Bottrill, L. Fairall, C. J. Smith, J. W. R. Schwabe, The structure of the core NuRD repression complex provides insights into its interaction with chromatin. *eLife* **5**, e13941 (2016).
63. A. Monfort, G. Di Minin, A. Postlmayr, R. Freimann, F. Arieti, S. Thore, A. Wutz, Identification of *Spen* as a crucial factor for *Xist* function through forward genetic screening in haploid embryonic stem cells. *Cell Rep.* **12**, 554–561 (2015).
64. B. Moindrot, A. Cerase, H. Coker, O. Masui, A. Grijzenhout, G. Pintacuda, L. Schermelleh, T. B. Nesterova, N. Brockdorff, A pooled shRNA screen identifies *Rbm15*, *Spen*, and *Wtap* as factors required for *Xist* RNA-mediated silencing. *Cell Rep.* **12**, 562–572 (2015).
65. A. R. Amândio, A. Necsulea, E. Joye, B. Mascrez, D. Duboule, *Hotair* is dispensable for mouse development. *PLoS Genet.* **12**, e1006232 (2016).
66. M. Portoso, R. Ragazzini, Ž. Brencić, A. Moiani, A. Michaud, I. Vassilev, M. Wassef, N. Servant, B. Sargueil, R. Margueron, PRC2 is dispensable for *HOTAIR*-mediated transcriptional repression. *EMBO J.* **36**, 981–994 (2017).
67. S. Kaneko, J. Son, R. Bonasio, S. S. Shen, D. Reinberg, Nascent RNA interaction keeps PRC2 activity poised and in check. *Genes Dev.* **28**, 1983–1988 (2014).
68. C. Cifuentes-Rojas, A. J. Hernandez, K. Sarma, J. T. Lee, Regulatory interactions between RNA and polycomb repressive complex 2. *Mol. Cell* **55**, 171–185 (2014).
69. M. Beltran, C. M. Yates, L. Skalska, M. Dawson, F. P. Reis, K. L. Fisher, C. R. Sibley, B. M. Foster, T. Bartke, J. Ule, R. G. Jenner, The interaction of PRC2 with RNA or chromatin is mutually antagonistic. *Genome Res.* **26**, 896–907 (2016).
70. M. Tachibana, K. Sugimoto, M. Nozaki, J. Ueda, T. Ohta, M. Ohki, M. Fukuda, N. Takeda, H. Niida, H. Kato, Y. Shinkai, G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. *Genes Dev.* **16**, 1779–1791 (2002).
71. J. J. Zyllicz, S. Dietmann, U. Günesdogan, J. A. Hackett, D. Cougot, C. Lee, M. A. Surani, Chromatin dynamics and the role of G9a in gene regulation and enhancer silencing during early mouse development. *eLife* **4**, e09571 (2015).
72. R. R. Pandey, T. Mondal, F. Mohammad, S. Enroth, L. Redrup, J. Komorowski, T. Nagano, D. Mancini-DiNardo, C. Kanduri, *Kcnq1ot1* antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. *Mol. Cell* **32**, 232–246 (2008).
73. A. Wagschal, H. G. Sutherland, K. Woodfine, A. Henckel, K. Chebli, R. Schulz, R. J. Oakey, W. A. Bickmore, R. Feil, G9a histone methyltransferase contributes to imprinting in the mouse placenta. *Mol. Cell Biol.* **28**, 1104–1113 (2008).
74. J. Fan, Y. Xing, X. Wen, R. Jia, H. Ni, J. He, X. Ding, H. Pan, G. Qian, S. Ge, A. R. Hoffman, H. Zhang, X. Fan, Long non-coding RNA *ROR* decoys gene-specific histone methylation to promote tumorigenesis. *Genome Biol.* **16**, 139 (2015).
75. B. Schuettengruber, A.-M. Martinez, N. Iovino, G. Cavalli, Trithorax group proteins: Switching genes on and keeping them active. *Nat. Rev. Mol. Cell Biol.* **12**, 799–814 (2011).
76. D. A. Lim, Y.-C. Huang, T. Swigut, A. L. Mirick, J. M. Garcia-Verdugo, J. Wysocka, P. Ernst, A. Alvarez-Buylla, Chromatin remodelling factor *Mill1* is essential for neurogenesis from postnatal neural stem cells. *Nature* **458**, 529–533 (2009).
77. L. Morey, A. Santanach, L. Di Croce, Pluripotency and epigenetic factors in mouse embryonic stem cell fate regulation. *Mol. Cell Biol.* **35**, 2716–2728 (2015).
78. K. A. McMahon, S. Y.-L. Hiew, S. Hadjur, H. Veiga-Fernandes, U. Menzel, A. J. Price, D. Kioussis, O. Williams, H. J. M. Brady, *Mill* has a critical role in fetal and adult hematopoietic stem cell self-renewal. *Cell Stem Cell* **1**, 338–345 (2007).
79. K. C. Wang, Y. W. Yang, B. Liu, A. Sanyal, R. Corces-Zimmerman, Y. Chen, B. R. Lajoie, A. Protacio, R. A. Flynn, R. A. Gupta, J. Wysocka, M. Lei, J. Dekker, J. A. Helms, H. Y. Chang, A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. *Nature* **472**, 120–124 (2011).
80. Y. W. Yang, R. A. Flynn, Y. Chen, K. Qu, B. Wan, K. C. Wang, M. Lei, H. Y. Chang, Essential role of lncRNA binding for WDR5 maintenance of active chromatin and embryonic stem cell pluripotency. *eLife* **3**, e02046 (2014).
81. C. Deng, Y. Li, L. Zhou, J. Cho, B. Patel, N. Terada, Y. Li, J. Bungert, Y. Qiu, S. Huang, *HoxB1nc* RNA recruits Set1/MLL complexes to activate *Hox* gene expression patterns and mesoderm lineage development. *Cell Rep.* **14**, 103–114 (2016).
82. P. Grote, L. Wittler, D. Hendrix, F. Koch, S. Wahrisch, A. Beisaw, K. Macura, G. Bläss, M. Kellis, M. Werber, B. G. Herrmann, The tissue-specific lncRNA *Fendrr* is an essential regulator of heart and body wall development in the mouse. *Dev. Cell* **24**, 206–214 (2013).
83. M. Delattre, A. Spierer, C. H. Tonka, P. Spierer, The genomic silencing of position-effect variegation in *Drosophila melanogaster*: Interaction between the heterochromatin-associated proteins Su(var)3-7 and HP1. *J. Cell Sci.* **113**, 4253–4261 (2000).
84. T. C. James, S. C. R. Elgin, Identification of a nonhistone chromosomal protein associated with heterochromatin in *Drosophila melanogaster* and its gene. *Mol. Cell Biol.* **6**, 3862–3872 (1986).
85. L. E. Norwood, T. J. Moss, N. V. Margaryan, S. L. Cook, L. Wright, E. A. Sefror, M. J. C. Hendrix, D. A. Kirschmann, L. L. Wallrath, A requirement for dimerization of HP1<sup>Hsc</sup> in suppression of breast cancer invasion. *J. Biol. Chem.* **281**, 18668–18676 (2006).
86. C. Muchardt, M. Guillemé, J.-S. Seeler, D. Trouche, A. Dejean, M. Yaniv, Coordinated methyl and RNA binding is required for heterochromatin localization of mammalian HP1 $\alpha$ . *EMBO Rep.* **3**, 975–981 (2002).
87. C. Maisson, D. Bailly, A. H. F. M. Peters, J.-P. Quivy, D. Roche, A. Taddei, M. Lachner, T. Jenuein, G. Almouzni, Higher-order structure in pericentric heterochromatin involves a distinct pattern of histone modification and an RNA component. *Nat. Genet.* **30**, 329–334 (2002).
88. C. Keller, R. Kulasegaran-Shylini, Y. Shimada, H.-R. Hotz, M. Bühler, Noncoding RNAs prevent spreading of a repressive histone mark. *Nat. Struct. Mol. Biol.* **20**, 1340 (2013).
89. H. Bierhoff, M. A. Dammert, D. Brocks, S. Dambacher, G. Schotta, I. Grummt, Quiescence-induced lncRNAs trigger H4K20 trimethylation and transcriptional silencing. *Mol. Cell* **54**, 675–682 (2014).
90. J. Gil, A. O’Loghlin, PRC1 complex diversity: Where is it taking us? *Trends Cell Biol.* **24**, 632–641 (2014).
91. E. Bernstein, E. M. Duncan, O. Masui, J. Gil, E. Heard, C. D. Allis, Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. *Mol. Cell Biol.* **26**, 2560–2569 (2006).
92. K. L. Yap, S. Li, A. M. Muñoz-Cabello, S. Raguz, L. Zeng, S. Mujtaba, J. Gil, M. J. Walsh, M.-M. Zhou, Molecular interplay of the noncoding RNA *ANRIL* and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of *INK4a*. *Mol. Cell* **38**, 662–674 (2010).
93. L. Yang, C. Lin, W. Liu, J. Zhang, K. A. Ohgi, J. D. Grinstein, P. C. Dorrestein, M. G. Rosenfeld, ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. *Cell* **147**, 773–788 (2011).
94. N. Vo, R. H. Goodman, CREB-binding protein and p300 in transcriptional regulation. *J. Biol. Chem.* **276**, 13505–13508 (2001).
95. A. J. Bannister, T. Kouzarides, The CBP co-activator is a histone acetyltransferase. *Nature* **384**, 641–643 (1996).
96. A. Postepska-Igielska, A. Giwojna, L. Gasri-Plotnitsky, N. Schmitt, A. Dold, D. Ginsberg, I. Grummt, lncRNA *Khps1* regulates expression of the proto-oncogene *SPHK1* via triplex-mediated changes in chromatin structure. *Mol. Cell* **60**, 626–636 (2015).
97. D. A. Bose, G. Donahue, D. Reinberg, R. Shiekhattar, R. Bonasio, S. L. Berger, RNA binding to CBP stimulates histone acetylation and transcription. *Cell* **168**, 135–149.e22 (2017).
98. C. T. Foster, O. M. Dovey, L. Lezina, J. L. Luo, T. W. Gant, N. Barlev, A. Bradley, S. M. Cowley, Lysine-specific demethylase 1 regulates the embryonic transcriptome and CoREST stability. *Mol. Cell Biol.* **30**, 4851–4863 (2010).
99. S. Hino, K. Kohroggi, M. Nakao, Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells. *Cancer Sci.* **107**, 1187–1192 (2016).
100. M.-C. Tsai, O. Manor, Y. Wan, N. Mosammaparast, J. K. Wang, F. Lan, Y. Shi, E. Segal, H. Y. Chang, Long noncoding RNA as modular scaffold of histone modification complexes. *Science* **329**, 689–693 (2010).
101. D. C. Zappulla, T. R. Cech, Yeast telomerase RNA: A flexible scaffold for protein subunits. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 10024–10029 (2004).
102. A. Porro, S. Feuerhahn, J. Lingner, TERRA-reinforced association of LSD1 with MRE11 promotes processing of uncapped telomeres. *Cell Rep.* **6**, 765–776 (2014).
103. A. Hermann, S. Schmitt, A. Jeltsch, The human Dnmt2 has residual DNA-(cytosine-C5) methyltransferase activity. *J. Biol. Chem.* **278**, 31717–31721 (2003).
104. M. G. Goll, F. Kirpekar, K. A. Maggert, J. A. Yoder, C.-L. Hsieh, X. Zhang, K. G. Golic, S. E. Jacobsen, T. H. Bestor, Methylation of tRNA<sup>Asp</sup> by the DNA methyltransferase homolog Dnmt2. *Science* **311**, 395–398 (2006).

105. N. Thakur, V. K. Tiwari, H. Thomassin, R. R. Pandey, M. Kanduri, A. Göndör, T. Grange, R. Ohlsson, C. Kanduri, An antisense RNA regulates the bidirectional silencing property of the *Kcnq1* imprinting control region. *Mol. Cell. Biol.* **24**, 7855–7862 (2004).
106. F. Mohammad, T. Mondal, N. Guseva, G. K. Pandey, C. Kanduri, *Kcnq1ot1* noncoding RNA mediates transcriptional gene silencing by interacting with Dnmt1. *Development* **137**, 2493–2499 (2010).
107. A. Di Ruscio, A. K. Ebralidze, T. Benoukraf, G. Amabile, L. A. Goff, J. Terragni, M. E. Figueroa, L. L. De Figueiredo Pontes, M. Alberich-Jorda, P. Zhang, M. Wu, F. D'Alò, A. Melnick, G. Leone, K. K. Ebralidze, S. Pradhan, J. L. Rinn, D. G. Tenen, DNMT1-interacting RNAs block gene-specific DNA methylation. *Nature* **503**, 371–376 (2013).
108. D. Qi, J. Li, B. Que, J. Su, M. Li, C. Zhang, M. Yang, G. Zhou, W. Ji, Long non-coding RNA DBCCR1-003 regulate the expression of DBCCR1 via DNMT1 in bladder cancer. *Cancer Cell Int.* **16**, 81 (2016).
109. F. Liu, F. Yang, X. Wu, J.-F. Huang, J.-H. Yuan, Q.-f. Tao, G.-h. Jiang, J.-s. Zheng, S.-H. Sun, Long non-coding RNA RBMY2FP promotes proliferation of male hepatocellular carcinoma by directing DNA methylation and activating RBMY1A1 via DNMT1. *Oncotarget* (2016).
110. G. Zhang, P.-O. Estève, H. G. Chin, J. Terragni, N. Dai, I. R. Corréa Jr., S. Pradhan, Small RNA-mediated DNA (cytosine-5) methyltransferase 1 inhibition leads to aberrant DNA methylation. *Nucleic Acids Res.* **43**, 6112–6124 (2015).
111. M. Okano, S. Xie, E. Li, Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. *Nat. Genet.* **19**, 219–220 (1998).
112. H. Gowher, A. Jeltsch, Enzymatic properties of recombinant Dnmt3a DNA methyltransferase from mouse: The enzyme modifies DNA in a non-processive manner and also methylates non-CpG sites. *J. Mol. Biol.* **309**, 1201–1208 (2001).
113. B. K. Sun, A. M. Deaton, J. T. Lee, A transient heterochromatic state in *Xist* preempts X inactivation choice without RNA stabilization. *Mol. Cell* **21**, 617–628 (2006).
114. C. Holz-Schietinger, N. O. Reich, RNA modulation of the human DNA methyltransferase 3A. *Nucleic Acids Res.* **40**, 8550–8557 (2012).
115. K.-M. Schmitz, C. Mayer, A. Postepska, I. Grummt, Interaction of noncoding RNA with the rDNA promoter mediates recruitment of DNMT3b and silencing of rRNA genes. *Genes Dev.* **24**, 2264–2269 (2010).
116. B. Picard, M. Wegnez, Isolation of a 75 particle from *Xenopus laevis* oocytes: A 5S RNA-protein complex. *Proc. Natl. Acad. Sci. U.S.A.* **76**, 241–245 (1979).
117. H. R. Pelham, D. D. Brown, A specific transcription factor that can bind either the 5S RNA gene or 5S RNA. *Proc. Natl. Acad. Sci. U.S.A.* **77**, 4170–4174 (1980).
118. D. R. Engelke, S.-Y. Ng, B. S. Shastry, R. G. Roeder, Specific interaction of a purified transcription factor with an internal control region of 5S RNA genes. *Cell* **19**, 717–728 (1980).
119. U. Guddat, A. H. Bakken, T. Pieler, Protein-mediated nuclear export of RNA: 5S rRNA containing small RNPs in *Xenopus* oocytes. *Cell* **60**, 619–628 (1990).
120. D. R. Setzer, S. R. Menezes, S. Del Rio, V. S. Hung, G. Subramanian, Functional interactions between the zinc fingers of *Xenopus* transcription factor IIIA during 5S rRNA binding. *RNA* **2**, 1254–1269 (1996).
121. T. Kino, D. E. Hurt, T. Ichijo, N. Nader, G. P. Chrousos, Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. *Sci. Signal.* **3**, ra8 (2010).
122. Y. Jeon, J. T. Lee, YY1 tethers *Xist* RNA to the inactive X nucleation center. *Cell* **146**, 119–133 (2011).
123. A. A. Sigova, B. J. Abraham, X. Ji, B. Molinje, N. M. Hannett, Y. E. Guo, M. Jangi, C. C. Giallourakis, P. A. Sharp, R. A. Young, Transcription factor trapping by RNA in gene regulatory elements. *Science* **350**, 978–981 (2015).
124. L. Zhou, K. Sun, Y. Zhao, S. Zhang, X. Wang, Y. Li, L. Lu, X. Chen, F. Chen, X. Bao, X. Zhu, L. Wang, L.-Y. Tang, M. A. Esteban, C.-C. Wang, R. Jauch, H. Sun, H. Wang, *Linc-YY1* promotes myogenic differentiation and muscle regeneration through an interaction with the transcription factor YY1. *Nat. Commun.* **6**, 10026 (2015).
125. D. C. C. Wai, M. Shihab, J. K. K. Low, J. P. Mackay, The zinc fingers of YY1 bind single-stranded RNA with low sequence specificity. *Nucleic Acids Res.* **44**, 9153–9165 (2016).
126. T. Hung, Y. Wang, M. F. Lin, A. K. Koegel, Y. Kotake, G. D. Grant, H. M. Horlings, N. Shah, C. Umbricht, P. Wang, Y. Wang, B. Kong, A. Langerød, A.-L. Børresen-Dale, S. K. Kim, M. van de Vijver, S. Sukumar, M. L. Whitfield, M. Kellis, Y. Xiong, D. J. Wong, H. Y. Chang, Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. *Nat. Genet.* **43**, 621–629 (2011).
127. S.-Y. Ng, R. Johnson, L. W. Stanton, Human long non-coding RNAs promote pluripotency and neuronal differentiation by association with chromatin modifiers and transcription factors. *EMBO J.* **31**, 522–533 (2012).
128. S.-Y. Ng, G. K. Bogu, B. S. Soh, L. W. Stanton, The long noncoding RNA *RMST* interacts with SOX2 to regulate neurogenesis. *Mol. Cell* **51**, 349–359 (2013).
129. A. T. Willingham, A. P. Orth, S. Batalov, E. C. Peters, B. G. Wen, P. Aza-Blanc, J. B. Hogenesch, P. G. Schultz, A strategy for probing the function of noncoding RNAs finds a repressor of NFAT. *Science* **309**, 1570–1573 (2005).
130. C.-T. Ong, V. G. Corces, CTCF: An architectural protein bridging genome topology and function. *Nat. Rev. Genet.* **15**, 234–246 (2014).
131. J. E. Phillips, V. G. Corces, CTCF: Master weaver of the genome. *Cell* **137**, 1194–1211 (2009).
132. S. Sun, B. C. Del Rosario, A. Szanto, Y. Ogawa, Y. Jeon, J. T. Lee, Jpx RNA activates *Xist* by evicting CTCF. *Cell* **153**, 1537–1551 (2013).
133. H. Yao, K. Brick, Y. Evrard, T. Xiao, R. D. Camerini-Otero, G. Felsenfeld, Mediation of CTCF transcriptional insulation by DEAD-box RNA-binding protein p68 and steroid receptor RNA activator SRA. *Genes Dev.* **24**, 2543–2555 (2010).
134. R. Saldaña-Meyer, E. González-Buendía, G. Guerrero, V. Narendra, R. Bonasio, F. Recillas-Targa, D. Reinberg, CTCF regulates the human p53 gene through direct interaction with its natural antisense transcript, *Wrap53*. *Genes Dev.* **28**, 723–734 (2014).
135. J. T. Kung, B. Kesner, J. Y. An, J. Y. Ahn, C. Cifuentes-Rojas, D. Colognori, Y. Jeon, A. Szanto, B. C. del Rosario, S. F. Pinter, J. A. Erwin, J. T. Lee, Locus-specific targeting to the X chromosome revealed by the RNA interactome of CTCF. *Mol. Cell* **57**, 361–375 (2015).
136. F. Yang, X. Deng, W. Ma, J. B. Berletch, N. Rabaia, G. Wei, J. M. Moore, G. N. Filippova, J. Xu, Y. Liu, W. S. Noble, J. Shendure, C. M. Distcheche, The lncRNA *Firre* anchors the inactive X chromosome to the nucleolus by binding CTCF and maintains H3K27me3 methylation. *Genome Biol.* **16**, 52 (2015).
137. X. Zhao, D. Li, J. Pu, H. Mei, D. Yang, X. Xiang, H. Qu, K. Huang, L. Zheng, Q. Tong, CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression. *Oncogene* **35**, 3565–3576 (2016).
138. J. Tang, S. Wu, H. Liu, R. Strat, O. G. Barak, R. Shiekhattar, D. J. Picketts, X. Yang, A novel transcription regulatory complex containing death domain-associated protein and the ATR-X syndrome protein. *J. Biol. Chem.* **279**, 20369–20377 (2004).
139. Y. Xue, R. Gibbons, Z. Yan, D. Yang, T. L. McDowell, S. Sechi, J. Qin, S. Zhou, D. Higgs, W. Wang, The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. *Proc. Natl. Acad. Sci. U.S.A.* **100**, 10635–10640 (2003).
140. M. Mitson, L. A. Kelley, M. J. E. Sternberg, D. R. Higgs, R. J. Gibbons, Functional significance of mutations in the Snf2 domain of ATRX. *Hum. Mol. Genet.* **20**, 2603–2610 (2011).
141. K. Sarma, C. Cifuentes-Rojas, A. Ergun, A. Del Rosario, Y. Jeon, F. White, R. Sadreyev, J. T. Lee, ATRX directs binding of PRC2 to *Xist* RNA and Polycomb targets. *Cell* **159**, 869–883 (2014).
142. K. Rippe, B. Luke, TERRA and the state of the telomere. *Nat. Struct. Mol. Biol.* **22**, 853–858 (2015).
143. J. Feng, C. Bi, B. S. Clark, R. Mady, P. Shah, J. D. Kohtz, The *Evf-2* noncoding RNA is transcribed from the *Dlx-5/6* ultraconserved region and functions as a *Dlx-2* transcriptional coactivator. *Genes Dev.* **20**, 1470–1484 (2006).
144. A. M. Bond, M. J. W. Vangompel, E. A. Sametsky, M. F. Clark, J. C. Savage, J. F. Disterhoft, J. D. Kohtz, Balanced gene regulation by an embryonic brain ncRNA is critical for adult hippocampal GABA circuitry. *Nat. Neurosci.* **12**, 1020–1027 (2009).
145. P. A. Latos, F. M. Pauler, M. V. Koerner, H. B. Senergin, Q. J. Hudson, R. R. Stocsits, W. Allhoff, S. H. Stricker, R. M. Klement, K. E. Warczok, K. Aumayr, P. Pasierbek, D. P. Barlow, *Airm* transcriptional overlap, but not its lncRNA products, induces imprinted *Igf2r* silencing. *Science* **338**, 1469–1472 (2012).
146. J. M. Engreitz, J. E. Haines, E. M. Perez, G. Munson, J. Chen, M. Kane, P. E. McDonel, M. Guttman, E. S. Lander, Local regulation of gene expression by lncRNA promoters, transcription and splicing. *Nature* **539**, 452–455 (2016).
147. K. M. Anderson, D. M. Anderson, J. R. McAnally, J. M. Shelton, R. Bassel-Duby, E. N. Olson, Transcription of the non-coding RNA upperhand controls *Hand2* expression and heart development. *Nature* **539**, 433–436 (2016).
148. J. A. Martens, L. Laprade, F. Winston, Intergenic transcription is required to repress the *Saccharomyces cerevisiae* SER3 gene. *Nature* **429**, 571–574 (2004).
149. S. L. Bumgarner, R. D. Dowell, P. Grisafi, D. K. Gifford, G. R. Fink, Toggle involving *cis*-interfering noncoding RNAs controls variegated gene expression in yeast. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 18321–18326 (2009).
150. M. Melé, J. L. Rinn, “Cat’s Cradling” the 3D genome by the act of lncRNA transcription. *Mol. Cell* **62**, 657–664 (2016).
151. C. M. Clemson, J. N. Hutchinson, S. A. Sara, A. W. Ensminger, A. H. Fox, A. Chess, J. B. Lawrence, An architectural role for a nuclear noncoding RNA: *NEAT1* RNA is essential for the structure of paraspeckles. *Mol. Cell* **33**, 717–726 (2009).
152. L. Sun, L. A. Goff, C. Trapnell, R. Alexander, K. A. Lo, E. Hacisuleyman, M. Sauvageau, B. Tazon-Vega, D. R. Kelley, D. G. Hendrickson, B. Yuan, M. Kellis, H. F. Lodish, J. L. Rinn, Long noncoding RNAs regulate adipogenesis. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 3387–3392 (2013).
153. E. Hacisuleyman, L. A. Goff, C. Trapnell, A. Williams, J. Henao-Mejia, L. Sun, P. McClanahan, D. G. Hendrickson, M. Sauvageau, D. R. Kelley, M. Morse, J. Engreitz, E. S. Lander, M. Guttman, H. F. Lodish, R. Flavell, A. Raj, J. L. Rinn, Topological

- organization of multichromosomal regions by the long intergenic noncoding RNA Firre. *Nat. Struct. Mol. Biol.* **21**, 198–206 (2014).
154. J. H. Bergmann, J. Li, M. A. Eckersley-Maslin, F. Rigo, S. M. Freier, D. L. Spector, Regulation of the ESC transcriptome by nuclear long noncoding RNAs. *Genome Res.* **25**, 1336–1346 (2015).
  155. J. S. Pflingsten, K. J. Goodrich, C. Taabazuing, F. Ouenzar, P. Chartrand, T. R. Cech, Mutually exclusive binding of telomerase RNA and DNA by Ku alters telomerase recruitment model. *Cell* **148**, 922–932 (2012).
  156. Z. Lu, Q. C. Zhang, B. Lee, R. A. Flynn, M. A. Smith, J. T. Robinson, C. Davidovich, A. R. Gooding, K. J. Goodrich, J. S. Mattick, J. P. Mesirov, T. R. Cech, H. Y. Chang, RNA duplex map in living cells reveals higher-order transcriptome structure. *Cell* **165**, 1267–1279 (2016).
  157. D. C. Zappulla, T. R. Cech, RNA as a flexible scaffold for proteins: Yeast telomerase and beyond. *Cold Spring Harb. Symp. Quant. Biol.* **71**, 217–224 (2006).
  158. A. R. Bassett, A. Akhtar, D. P. Barlow, A. P. Bird, N. Brockdorff, D. Duboule, A. Ephrussi, A. C. Ferguson-Smith, T. R. Gingeras, W. Haerty, D. R. Higgs, E. A. Miska, C. P. Ponting, Considerations when investigating lncRNA function in vivo. *eLife* **3**, e03058 (2014).
  159. L. S. Qi, M. H. Larson, L. A. Gilbert, J. A. Doudna, J. S. Weissman, A. P. Arkin, W. A. Lim, Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell* **152**, 1173–1183 (2013).
  160. Y.-Y. Tseng, B. S. Moriarity, W. Gong, R. Akiyama, A. Tiwari, H. Kawakami, P. Ronning, B. Reuland, K. Guenther, T. C. Beadnell, J. Essig, G. M. Otto, M. G. O'Sullivan, D. A. Largaespada, K. L. Schwertfeger, Y. Marahrens, Y. Kawakami, A. Bagchi, *PVT1* dependence in cancer with *MYC* copy-number increase. *Nature* **512**, 82–86 (2014).
  161. I. Martianov, A. Ramadass, A. Serra Barros, N. Chow, A. Akoulitchev, Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. *Nature* **445**, 666–670 (2007).
  162. I. Shamovsky, M. Ivannikov, E. S. Kandel, D. Gershon, E. Nudler, RNA-mediated response to heat shock in mammalian cells. *Nature* **440**, 556–560 (2006).
  163. S. L. Bumgarner, G. Neuert, B. F. Voight, A. Symbor-Nagrabaska, P. Grisafi, A. van Oudenaarden, G. R. Fink, Single-cell analysis reveals that noncoding RNAs contribute to clonal heterogeneity by modulating transcription factor recruitment. *Mol. Cell* **45**, 470–482 (2012).
  164. H. Maamar, M. N. Cabili, J. Rinn, A. Raj, *linc-HOXA1* is a noncoding RNA that represses *Hoxa1* transcription in cis. *Genes Dev.* **27**, 1260–1271 (2013).

**Acknowledgments:** We appreciate helpful discussions and suggestions from J. L. Rinn, J. A. Goodrich, and J. F. Kugel (all from University of Colorado Boulder). **Funding:** T.R.C. is an investigator of the Howard Hughes Medical Institute, which provided funding in support of this work. This work was also supported by a grant from the NIH (GM099705 to T.R.C.). **Author contributions:** All authors contributed to the writing of this article. **Competing interests:** T.R.C. is on the board of directors of Merck Inc., which provides no funding for his research. The other authors declare that they have no competing interests. **Data and materials availability:** All data needed to evaluate the conclusions in the paper are present in the articles cited herein.

Submitted 26 June 2017

Accepted 12 September 2017

Published 27 September 2017

10.1126/sciadv.aao2110

**Citation:** Y. Long, X. Wang, D. T. Youmans, T. R. Cech, How do lncRNAs regulate transcription? *Sci. Adv.* **3**, eaao2110 (2017).